Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been long CVM for a couple of years now,and if the company is a fraud, so be it; I've been duped. My holdings are not worth unloading and they a reminder to be more diligent before investing.
I have a question for the board. Since I no longer follow CVM closely, forgive me if this is common knowledge: The Multikine trial is wrapping up, awaiting 289 "events" in order to determine the drug's benefit on life extension. Is there an official number of these "events" that have already occurred? And at what date was that number determined. Are we waiting for 5 more? 25? 100?
Am I correct in deducing that the longer it takes to get to 289, the more effective Multikine is?
Thanks,
gh
Bankruptcy cannot occur without default on an outstanding debt.
What debt do you know of that puts IPIX in such jeopardy???
FUD
gh
Here's a suggestion for IHUB insiders: How about showing the latest share price as of the time of each post.
gh
I often wonder, in the aftermath of their bankruptcy, if any of the PolyMedix crew or University collaborators are IPIX investors, or IHUB posters. The demise of PolyMedix must have been devastating to many. The future of IPIX could be vindication for their hard work that seemed unfulfilled years ago. The IPIX low share price is a window of opportunity for relieving the pain of the bankruptcy. If they're not here yet, now might be a good time to get in.
gh
I may be a cockeyed optimist, but the thought of selling the last 6k shares of IPIX at this time seems irrational. The ONLY bad news about this company is the share price lead by very minimal dilution and the outstanding FUD drumbeat that frightens newcomers doing DD here. Keep the 6k shares and just pretend that you sold them. Don't follow the company daily; just monthly. In a few years you'll be glad you did. By then the FUDsters will be gone or switch to long positions and changed their names, becoming cheerleaders.
JMO.
gh
With all the big $$$ deals in the IBD/ Chrones/ UP space, have there been any of the durg candidates that have shown pictures of before and after clearance of inflammation as have we?
I just got the company email notice time stamped at 10:44 pm.
gh
I wonder, what might be going through Mr. Aruda's mind tonight???
gh
I, for one am very much in favor of a bidding war with lots of rich suitors.
gh
As Dr. Bertolino said in the June 26 press release,"...The endoscopic evidence we have now gathered on patients is particularly telling".
I've posted before that that this photographic (dare I hope for video?) evidence will be included in the upcoming presentation.
Question for the board: Would it be advisable for the company to post the visual evidence in advance of the presentation to generate "buzz"?
gh
Thanks Hound, I stand corrected.
gh
Sox
quote...After Aspire there's a $45M shelf registration.
I am under the impression that the shelf registration is for 45 million SHARES rather than $$$.
gh
I'd like to see an appendix with next week's presentation slide deck with side by side, before and after endoscopic pictures of each trial participant. Explanatory circles and arrows will show the effectiveness of our drug...A picture is worth a thousand words.
gh
While I eagerly await tomorrow's presentation, its my opinion that this is not likely the time for any partnership announcement. Updates of trial progression may not have dramatic market effect, but steady recovery of the share price is my hope.
The explosive upsurge will only occur when some Big Pharma partnership or other type deal is announced.
gh
Look out below!
http://www.nbcnews.com/storyline/americas-heroin-epidemic/dangerously-addictive-painkiller-prescribed-patients-who-shouldn-t-have-received-n767311
Prime time Megan Kelly's NBC debut included an expose' of Subsys.
gh
How about B chewing gum to prevent cavities and gum disease?
gh
Are you using the same PI that the Rosen Law Firm uses? Or maybe MAKO?
Claptrap!
Without DEBT there will be no bankruptcy.
I just saw a program on c-span where the moderator interviews Ira Boudway, a writer for Bloomberg/Business Week. They discussed CTE and at about the 7 minute mark Aethlon and Exasome are discussed.
https://www.c-span.org/video/?426630-5/washington-journal-ira-boudway-discusses-concussion-technology-nfl
gh
The possibilities are manifold.
How about a nasal spry for allergies?
gh
Scott Gottllieb appointed by Trump to lead FDA.
https://www.forbes.com/sites/matthewherper/2017/03/10/the-best-stories-scott-gottlieb-the-next-fda-commissioner-wrote-for-forbes/#50b496a4c523
Any thoughts?
gh
Correct?
Is my math correct? A $40 Billion buyout would yield an approximate share price of $320. I'd sell some at that price! :)
gh
NEWS:
BEVERLY, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced interim results in the first two cohorts of its ongoing Phase 2a clinical trial of Brilacidin for the induction of remission of mild-to-moderate Ulcerative Colitis. Patient recruitment to the third cohort (highest dose) is currently underway. Patients include those with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).
The ongoing Phase 2, open-label, Proof-of-Concept (PoC) trial comprises three sequential cohorts (6 patients per cohort), with progressive dose escalation by cohort—50 mg (Cohort A), 100 mg (Cohort B), and 200 mg (Cohort C), respectively. Daily treatment with Brilacidin by enema administration is performed consecutively for 42 days.
All twelve (12) patients across the first two cohorts have completed their full dosing schedules in the study. Comparison to baseline after six weeks of treatment showed:
All 12 patients experienced a beneficial response, as measured by the Modified Mayo Disease Activity Index (MMDAI).
-- At Day 42, the Primary Efficacy Endpoint of Clinical Remission (accounting for Stool Frequency, Rectal Bleeding, and Endoscopy sub-scores), was met in half (n=6) of all patients (3 of 6 in Cohort A; 3 of 6 in Cohort B).
-- Among the remaining patients (n=6) in Cohorts A and B not meeting all three criteria for Clinical Remission, two of the three criteria were achieved by all of these patients (defined as a Partial Response).
Patient Quality-of-Life, as assessed by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), was improved in all 12 patients after six weeks of daily Brilacidin treatment. Specifically, over 40 percent of patients reported significant improvements, ranging approximately from 20 points to more than 50 points higher on the 70-point SIBDQ scale.
Brilacidin was generally well-tolerated and patients maintained stable normal vital signs during treatment.
Measurements of drug concentrations in plasma continued to show limited systemic absorption of Brilacidin, with all values registering less than 100 ng/mL for all six patients in Cohort A and averaging approximately 200 ng/mL maximum concentrations across the six patients in Cohort B.
Patients for Cohort C (200 mg, the highest and final dosing group) are now being enrolled. Further detailed analyses, across all three cohorts once the trial is completed, will establish which dosing level provides the most favorable overall outcomes.
gh
Is there some reason why the company cannot sell some of its shelf registered shares in the market bypassing the Aspire process?
gh
I couldn't figure how to actually post the image, but here's a link to it:
http://www.businessinsider.com/what-success-looks-like-2012-4
gh :)
NOT a great idea unless the Big Pharma pays up BIG TIME in advance. If they would buy CTIX for the prospect of a valuable top 3 (P, B, and K), fine. But these are shrewd business pros,who will not give away anything.
I say let them bid for one drug at a time, Pay for either a partnership with a large royalty for P or a whole lot more for all of P. That will put Ctix in a position to develop B and K AND the rest of our closet full of other unexplored wonder-drugs for maximum value.
If CTIX sells itself, and then our drugs perform as we expect, The Big Pharma will do well. But what are the chances of a JNJ or Celgene doubling much less 5X or 10X because of any one drug?
Either way we have to get the benefit UP FRONT. I think this is Leo's approach too.
imo.
gh
We have a whole deck of potential 'river cards' developed by Dr. Menon:
http://cellceutix.com/pre-clinical-compounds/#sthash.cDyhWtvX.pBItoqZY.dpbs
In addition we have the Polyheist assets awaiting the funding for advancement.
Three aces plus a trove of unappreciated wild cards yet to be priced into our CTIX share value!
Let us give thanks.
gh
It has been confirmed by a reliable source that the drug candidates listed starting with Dr. Menon's initials were developed before the Polyheist. We got Brilacidin and several other valuable compounds with patents from PolyMedix. We must exploit all these potential cures for the good of mankind, and for our personal financial benefit. However, we must be prudent, as PolyMedix was not, to spend wisely. Leo has been an excellelnt steward of our resources, giving us a great opportunity for success, imo.
gh
The drugs you refer to here are notated with the initials of Dr. Menon. Were these developed by him or are these the compounds that were from the Polyheist that were not the front-runners for the scarce development dollars in our coffers?
gh
"Is Aspire trapped? Why have they let the share price increase in the last few days?"
Perhaps they see the golden opportunity in not continuing to sell shares into the market at our low share price. If they buy low and hold for a while, they could profit from the rising price.
Buy low; sell high. What a concept!
gh
KarinCA, I hope you're OK; we haven't heard from you lately. This board is much diminished without your wisdom and calming presence:)
gh
Has anyone found any video presentations by any of our 'new hires'?
If so please post a link.
Thanks,
gh
Has anyone seen a video clip of Dr. Arthur Bertolino, MD?
A man of his experience should have some video history forever in cyberspace.
The limited search that I performed was just on Youtube and the first page of Google.
gh
Seems like the lightest traffic on this board in memory. Maybe the weak hands have sold.
gh
FWIW, I have emailed the author and a few folks at the Pew Research Center, enlightening them about about their error:
"There have been no new classes of antibiotics discovered since 1984, according to Pew’s antibiotic-resistance project."
and recommended that they contact the company directly.
https://www.washingtonpost.com/news/to-your-health/wp/2016/07/28/major-global-partnership-to-speed-antibiotic-development-launched/
gh
Who does that?
Those invested in a glue factory. FUD mongers hoping for CTIX to fail.
In reply to Boo Dog: "Giving Bertolino a chance to take the helm I think is a great idea. And kudos to Leo for bringing him onboard.
Now let's see if he can really make a difference. The pipeline at this stage warrants bringing him in and he has the track record to push our drugs through the final stages from where they are now. Get the right attention, he'll certainly be able to help make the right connections, and funding commitments. Think some are just shooting the horse in the foot right out of the gate. Who does that?"
gh
Its past my bedtime and after 3 glasses of wine, I'm unable to find a video clip of our Arthur P. Bertolino making a presentation to either a conference or to a media outlet. I leave it to our night owls, our west coasters or our Hawaiian posters who might not be impaired, to find such historical evidence....
The PR said he's been a "contributor to major media broadcasts".
Let's see what we've got.
gh